Loading clinical trials...
Loading clinical trials...
Phase II, Double-Blind, Placebo-Controlled Study to Explore the ELF and Plasma Concentration as Well as Safety of Inhaled Alpha-1 Antitrypsin in Alpha-1 Antitrypsin Deficiency Subjects
Conditions
Interventions
Kamada-AAT for Inhalation, 80mg
Placebo
+1 more
Locations
2
United States
University of Florida, Pulmonary, Critical Care & Sleep Medicine
Gainesville, Florida, United States
The University of Texas Health Science Center at Tyler Center for Clinical Research
Tyler, Texas, United States
Start Date
April 1, 2014
Primary Completion Date
February 1, 2016
Completion Date
May 1, 2016
Last Updated
January 18, 2020
NCT00500123
NCT02796937
NCT02900183
NCT06186492
NCT03815396
NCT03767829
Lead Sponsor
Kamada, Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions